scholarly journals Severe Sepsis Caused by Bacteria That Entered via the Intestinal Tract: A Case of Crohn's Disease in a Child

Cureus ◽  
2020 ◽  
Author(s):  
Kasumi Satoh ◽  
Manabu Okuyama ◽  
Tomoki Furuya ◽  
Yasuhito Irie ◽  
Hajime Nakae
Keyword(s):  
Severe Sepsis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Intestinal Tract

scholarly journals Improvement with Infliximab of a Disseminated Sarcoidosis in a Patient with Crohn’s Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Nader Chebib ◽  
Fabrice Piégay ◽  
Julie Traclet ◽  
François Mion ◽  
Jean-François Mornex
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Ct Scan ◽  
Rare Case ◽  
Intestinal Tract ◽  
Chest Ct ◽  
Steroid Resistant ◽  
Abnormal Chest ◽  
History Of ◽  
Chest Ct Scan

Sarcoidosis and Crohn’s disease are systemic granulomatous disorders affecting the lung and the intestine, respectively, with variable involvement of other organs and are seldom associated. While anti-TNFαis a recognized treatment of Crohn’s disease, its usage is discussed in sarcoidosis. A 42-year-old man presented with an 11-year-long history of Crohn’s disease; upon discovery of an abnormal chest CT scan the diagnosis of multivisceral sarcoidosis was made and, later, a treatment with an anti-TNFαagent, infliximab, was started, because of worsening Crohn’s disease recurrences. CT scan demonstrated net regression of pulmonary opacities and hepatosplenic lesions. Pathologies obtained from the intestinal tract and the bronchi of the patient were, respectively, characteristic of Crohn’s disease and sarcoidosis leading to the diagnosis of both diseases. We report a rare case of steroid resistant Crohn’s disease associated with multivisceral sarcoidosis, treated successfully by an anti-TNFαagent, infliximab.

scholarly journals Tabulation of Myeloid, Lymphoid and Intestinal Malignancies in Crohn’s Disease

2002 ◽  
Vol 16 (11) ◽  
pp. 779-784 ◽  
Author(s):  
Hugh J Freeman
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Intestinal Tract ◽  
Disease Process ◽  
Extended Period ◽  
Single Male ◽  
Lymphoid Malignancies ◽  
Definition Of

A variety of malignant complications occur in Crohn’s disease, and previous studies have recorded an increased intestinal cancer risk. The present investigation tabulated myeloid and lymphoid malignancies compared with intestinal cancers in 1000 consecutively evaluated patients with Crohn’s disease who were followed over an extended period by a single clinician. Myeloid and lymphoid neoplasms were present in 0.5% of patients, while cancer in the intestinal tract was detected in 1%. Most of these patients with a malignancy had Crohn’s disease for a prolonged period of more than 20 years and had negative outcomes, including death or presentations with advanced disease. In this cohort, lymphoma was not detected in a single patient after definition of Crohn’s disease, possibly reflecting the limited use of immunosuppressives or infused biological agents in this clinical practice. Bypassed rectal ‘stumps’ were associated with subsequent colorectal cancer in half of all males with colon cancer in this series, suggesting an important risk factor following colectomy in Crohn’s disease. Epithelial dysplasia was detected in only a single male patient before colorectal cancer, implying that this histopathological marker may be a poor predictor of subsequent colon cancer development in Crohn’s disease, an inflammatory bowel disease process that is typically patchy or focal in distribution in the intestinal tract.

scholarly journals TRANSPLANTATION OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN REFRACTORY CROHN’S DISEASE: SYSTEMATIC REVIEW

2019 ◽  
Vol 32 (4) ◽  
Author(s):  
Luana BERNARDI ◽  
Carlos Henrique Marques dos SANTOS ◽  
Verônica Assalin Zorgetto PINHEIRO ◽  
Rodrigo Juliano OLIVEIRA ◽  
Andreia Conceição Milan Brochado ANTONIOLLI-SILVA
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Intestinal Tract ◽  
Pathological Condition ◽  
Absorbable Suture ◽  
Keywords Crohn's Disease ◽  
Subcutaneous Adipose ◽  
Luminal Region

ABSTRACT Background: Crohn’s disease is a pathological condition that has different options of treatment, but there are patients who need other therapeutic approach, such as the use of adipose-derived mesenchymal stem cells. Aim: Systematic literature review to determine the different ways of adipose-derived mesenchymal stem cells administration in humans with luminal refractory and perianal fistulizing Crohn’s disease. Methods: It was conducted a search for articles (from 2008 to 2018) on PubMed and ScienceDirect databases using the keywords Crohn’s disease, fistulizing Crohn’s disease, luminal Crohn’s disease and transplantation of mesenchymal stem cells or mesenchymal stem cells or stromal cells. Thirteen publications were selected for analysis. Results: Only one study referred to the luminal Crohn´s disease. The number of cells administered was variable, occurring mainly through subcutaneous adipose tissue by liposuction. It could be highlighted the autologous transplant with exclusive infusion of mesenchymal stem cells. The procedures involved in pre-transplant were mainly curettage, setons placement and stitching with absorbable suture, and conducting tests and drug treatment for luminal Crohn´s disease. During transplant, the injection of mesenchymal stem cells across the fistula path during the transplant was mainly on the intestinal tract wall. Conclusion: Although the use of mesenchymal stem cells is promising, the transplant on the luminal region should be more investigated. The injection of mesenchymal stem cells, exclusively, is more explored when compared to treatment with other products. The preparation of the fistulizing tract and the location of cell transplantation involve standardized health care in most studies.

scholarly journals Activating transcription factor 3 (ATF3) as a perspective biomarker of Crohn’s disease

2020 ◽  
Vol 18 ◽  
pp. 205873922092979
Author(s):  
Nobuyuki Kobayashi ◽  
Seiji Arihiro ◽  
Kazuya Shimada ◽  
Atsushi Hoshino ◽  
Hiroki Saijo ◽  
...  
Keyword(s):  
Transcription Factor ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Mouse Model ◽  
Intestinal Tract ◽  
Human Subjects ◽  
Activating Transcription Factor 3 ◽  
Chemically Induced ◽  
Activating Transcription Factor ◽  
Transcription Factor 3

Introduction: Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the intestinal tract. Known types are Crohn’s disease (CD) and ulcerative colitis (UC), but their cause remains unclear and there is no convenient biomarker for IBD. The present study aimed to demonstrate an association between the onset of CD and activating transcription factor 3 (ATF3); as a new biomarker, measurement of blood ATF3 mRNA would be useful for distinguishing between CD and UC. Methods: First, in a mouse model of IBD in which damage to the intestinal mucosa was chemically induced with dextran sulfate sodium (DSS), intestinal ATF3 mRNA was evaluated. Next, in human subjects, CD and UC patients, blood ATF3 mRNA and intestinal ATF3 protein production were evaluated. Results: In the mouse model of IBD, intestinal ATF3 mRNA was elevated compared with the control ( P < 0.0001). In CD patients, blood ATF3 mRNA was elevated as compared with normal controls (NCs) and UC patients ( P < 0.05). In addition, we observed an increase in ATF3 production in the intestinal tract specific to CD. Conclusion: ATF3 is involved in the onset of CD, and blood ATF3 mRNA measurements would be useful for distinguishing it from UC.

Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)?

2019 ◽  
Vol 20 (13) ◽  
pp. 1369-1372 ◽  
Author(s):  
Hang Hock Shim ◽  
Christopher Ma ◽  
Paulo Gustavo Kotze ◽  
Remo Panaccione
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Intestinal Tract ◽  
Biologic Therapy ◽  
Safety Data ◽  
Biologic Therapies ◽  
Intestinal Surgery ◽  
Tnf Antagonists ◽  
Number Of Patients ◽  
Chronic Inflammatory Condition

Crohn’s disease (CD) is a chronic inflammatory condition of the intestinal tract that is characterised by a relapsing and remitting course. Despite advancements in therapeutic options for CD, a substantial number of patients still require surgery for medically refractory disease or disease-related complications. Given the widespread adoption of biologic therapies for the management of patients with moderate-to-severe CD, a high number of patients are likely to be on biologic therapy at the time of needing intestinal surgery: the safety of biologics in perioperative setting is of great interest. While more clinical data are available for TNF antagonists and vedolizumab, the safety data for ustekinumab, an IL 12/23 inhibitor, is lacking. Here, we review the available data from published literature on the postoperative outcomes for CD patients exposed to ustekinumab perioperatively.

Sign in / Sign up

Export Citation Format

Share Document